ATR分子通路及其抑制剂抗肿瘤研究进展  

Research Advances in ATR Pathways and Inhibitors for Antitumor Therapy

作　　者：冯春来[1] 吴文凡 

机构地区：[1]江苏大学药学院,江苏镇江212013

出　　处：《医学综述》2017年第22期4419-4426,共8页Medical Recapitulate

基　　金：国家自然科学基金(81373897);江苏省博士后科研基金(1402174C);江苏大学高级专业人才科研启动基金(12JDG034)

摘　　要：共济失调毛细血管扩张突变基因Rad3相关激酶(ATR)是一种DNA损伤修复应答(DDR)机制的重要调节因子。研究发现,ATR分子通路通过多种细胞因子调控细胞DNA损伤修复,进而致使正常细胞发展为肿瘤细胞。ATR激酶也是一种能够抗肿瘤且不影响正常细胞的理想靶标,其抑制剂的开发引起广泛关注。目前,已经有相当多的ATR激酶抑制剂被开发出来,其中部分抑制剂展现出了显著的抑瘤效果,且已进入临床试验阶段,其单用或与其他药物联用的疗效和安全性有待进一步临床验证。Ataxia telangiectasia and Rad3-related （ATR） is an important regulatory factor for the DNA damage response（DDR） mechanism. The research found that ATR molecular pathway regulates cell DNA damage repair through a variety of cytokines, which leads to the development of normal cells into tumor cells. ATR is also an ideal antitumor target without affecting normal cells. In recent years, the development of ATR inhibitors has attracted wide attention, and a consid- erable number of ATR kinase inhibitors have been developed, some of which have shown a significant anti-tumor effect, and have entered the clinical trial, and the efficacy and safety of its alone or in combination with other drugs still need further clinical validation.

关 键 词：共济失调毛细血管扩张突变基因Rad3相关激酶分子通路 共济失调毛细血管扩张突变基因Rad3相 关激酶抑制剂 肿瘤 靶点 

分 类 号：R322[医药卫生—人体解剖和组织胚胎学]